BRAIN and NERVE－神経研究の進歩70巻5号

2018年05月発行

総説

2016WHO中枢神経系腫瘍分類—組織分類から分子分類への転換

著者： 廣瀬隆則¹²

所属機関： ¹神戸大学大学院医学研究科地域連携病理学 ²兵庫県立がんセンター病理診断科

ページ範囲：P.543 - P.550

文献概要

脳腫瘍の分子遺伝学的解析の発展を背景に，2016年にWHO中枢神経系腫瘍分類が改訂された。今回の改訂で脳腫瘍分類は，従来の組織分類から分子分類へと大きく転換された。特にびまん性膠腫群と胎児性腫瘍群で，組織診断名に分子情報を加えた統合診断名が導入された。この新分類により，脳腫瘍の診断精度の向上，適切な治療選択，精密な予後予測などが期待される。現在，診療現場で新分類に対する対応が始まっている。

参考文献

1) Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): WHO Classification of Tumours of the Central Nervous System, revised 4th edition. World Health Organization, Lyon, 2016

2) Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, et al: International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24: 429-435, 2014

3) Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, et al: The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131: 803-820, 2016

4) Louis DN, Ohgaki H, Wiestler OD, Cavenee W (eds): WHO Classification of Tumours of the Central Nervous System, 4th edition, World Health Organization, Lyon, 2007

5) Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773, 2009

6) Brandner S, von Deimling A: Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Neuropathol Appl Neurobiol 41: 694-720, 2015

7) Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, et al: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145: 1175-1190, 1994

8) Wesseling P, van den Bent M, Perry A: Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol 129: 809-827, 2015

9) Aldape K, Burger PC, Perry A: Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 131: 242-251, 2007

10) Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, et al: Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 128: 551-559, 2014

11) Arita H, Narita Y, Yoshida A, Hashimoto N, Yoshimine T, et al: IDH1/2 mutation detection in gliomas. Brain Tumor Pathol 32: 79-89, 2015

12) Capper D, Weissert S, Balss J, Habel A, Meyer J, et al: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20: 245-254, 2010

13) Hirose T, Ishizawa K, Shimada S: Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors. Neuropathology 30: 586-596, 2010

14) Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, et al: Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123: 465-472, 2012

15) Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, et al: Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 121: 381-396, 2011

16) Paulus W, Kleihues P: Genetic profiling of CNS tumors extends histological classification. Acta Neuropathol 120: 269-270, 2010

17) Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, et al: Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathol 133: 1-3, 2017